These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 33339860)
1. Prognostic relevance of programmed cell death 1 ligand 2 (PDCD1LG2/PD-L2) in patients with advanced stage colon carcinoma treated with chemotherapy. Huang KC; Chiang SF; Chen TW; Chen WT; Yang PC; Ke TW; Chao KSC Sci Rep; 2020 Dec; 10(1):22330. PubMed ID: 33339860 [TBL] [Abstract][Full Text] [Related]
2. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers. Kim MY; Koh J; Kim S; Go H; Jeon YK; Chung DH Lung Cancer; 2015 Apr; 88(1):24-33. PubMed ID: 25662388 [TBL] [Abstract][Full Text] [Related]
3. Clinical significance of programmed cell death-ligand expression in small bowel adenocarcinoma is determined by the tumor microenvironment. Hoshimoto A; Tatsuguchi A; Hamakubo R; Nishimoto T; Omori J; Akimoto N; Tanaka S; Fujimori S; Hatori T; Shimizu A; Iwakiri K World J Gastroenterol; 2023 Oct; 29(40):5566-5581. PubMed ID: 37970475 [TBL] [Abstract][Full Text] [Related]
4. Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma. Gao Y; Li S; Xu D; Chen S; Cai Y; Jiang W; Zhang X; Sun J; Wang K; Chang B; Wang F; Hong M Chin J Cancer; 2017 Jul; 36(1):61. PubMed ID: 28754154 [TBL] [Abstract][Full Text] [Related]
5. High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients. Ludovini V; Bianconi F; Siggillino A; Vannucci J; Baglivo S; Berti V; Tofanetti FR; Reda MS; Bellezza G; Mandarano M; Belladonna ML; Metro G; Chiari R; Sidoni A; Puma F; Minotti V; Roila F Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33671892 [TBL] [Abstract][Full Text] [Related]
6. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma. Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759 [TBL] [Abstract][Full Text] [Related]
7. Clinical significance of programmed death 1 ligand-1 (CD274/PD-L1) and intra-tumoral CD8+ T-cell infiltration in stage II-III colorectal cancer. Huang CY; Chiang SF; Ke TW; Chen TW; You YS; Chen WT; Chao KSC Sci Rep; 2018 Oct; 8(1):15658. PubMed ID: 30353144 [TBL] [Abstract][Full Text] [Related]
8. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer. Peng QH; Wang CH; Chen HM; Zhang RX; Pan ZZ; Lu ZH; Wang GY; Yue X; Huang W; Liu RY J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579737 [TBL] [Abstract][Full Text] [Related]
9. Programmed Death-Ligand 1 and Programmed Death-Ligand 2 Expression Can Affect Prognosis in Extramammary Paget's Disease. Kawaguchi A; Akiba J; Kondo R; Sadashima E; Ogasawara S; Naito Y; Kusano H; Sanada S; Muto I; Nakama T; Yano H Anticancer Res; 2021 Jan; 41(1):219-226. PubMed ID: 33419816 [TBL] [Abstract][Full Text] [Related]
10. Prognostic value of programed death ligand-1 and ligand-2 co-expression in salivary gland carcinomas. Nakano T; Takizawa K; Uezato A; Taguchi K; Toh S; Masuda M Oral Oncol; 2019 Mar; 90():30-37. PubMed ID: 30846173 [TBL] [Abstract][Full Text] [Related]
11. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients. El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185 [TBL] [Abstract][Full Text] [Related]
12. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas. Kim S; Kim MY; Koh J; Go H; Lee DS; Jeon YK; Chung DH Eur J Cancer; 2015 Nov; 51(17):2698-707. PubMed ID: 26329973 [TBL] [Abstract][Full Text] [Related]
13. The Prognostic Significance of the Tumor-infiltrating Programmed Cell Death-1 Shibutani M; Maeda K; Nagahara H; Fukuoka T; Nakao S; Matsutani S; Hirakawa K; Ohira M Anticancer Res; 2017 Aug; 37(8):4165-4172. PubMed ID: 28739701 [TBL] [Abstract][Full Text] [Related]
14. PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma. Furuse M; Kuwabara H; Ikeda N; Hattori Y; Ichikawa T; Kagawa N; Kikuta K; Tamai S; Nakada M; Wakabayashi T; Wanibuchi M; Kuroiwa T; Hirose Y; Miyatake SI BMC Cancer; 2020 Apr; 20(1):277. PubMed ID: 32248797 [TBL] [Abstract][Full Text] [Related]
15. Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer. Masugi Y; Nishihara R; Hamada T; Song M; da Silva A; Kosumi K; Gu M; Shi Y; Li W; Liu L; Nevo D; Inamura K; Cao Y; Liao X; Nosho K; Chan AT; Giannakis M; Bass AJ; Hodi FS; Freeman GJ; Rodig SJ; Fuchs CS; Qian ZR; Nowak JA; Ogino S Cancer Immunol Res; 2017 Nov; 5(11):1046-1055. PubMed ID: 29038297 [TBL] [Abstract][Full Text] [Related]
17. Intratumoral Cytotoxic T-Lymphocyte Density and PD-L1 Expression Are Prognostic Biomarkers for Patients with Colorectal Cancer. Calik I; Calik M; Turken G; Ozercan IH; Dagli AF; Artas G; Sarikaya B Medicina (Kaunas); 2019 Oct; 55(11):. PubMed ID: 31683723 [No Abstract] [Full Text] [Related]
18. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study. Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075 [TBL] [Abstract][Full Text] [Related]
19. Prognostic value of tumor PD-L1 expression combined with CD8 Wang Q; Lou W; Di W; Wu X Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888 [TBL] [Abstract][Full Text] [Related]
20. High Expression of Programmed Death Ligand 1 and Programmed Death Ligand 2 in Ophthalmic Sebaceous Carcinoma: The Case for a Clinical Trial of Checkpoint Inhibitors. Wolkow N; Jakobiec FA; Afrogheh AH; Pai SI; Faquin WC Am J Ophthalmol; 2020 Dec; 220():128-139. PubMed ID: 32730911 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]